Jesse Chu

Commercial leader and value investor with proven success in driving sustainable growth through investment and performance optimization.

📍 United States🔄 Updated September 2026💼 2 investments📅 19 years investing🗓 Last invested Dec 2018
Angel investor🌍 United States
2
Total investments
0
Early stage
0
Mid stage
1
Late stage
19y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Biotech Investor
Dec 2018
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT
Experience · 3 entries
All (3)
Investments (2)
2018
Biotech Investor
Dec 2018
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT
2014
Associate Director of Business Analysis
Jan 2014
Life Technologies is now part of Thermo Fisher Scientific. To see what’s new, go to https://www.linkedin.com/company/thermo-fisher-scientific Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
2007
Tech Investor
Sep 2007
Xilinx was founded in Silicon Valley in 1984 and was the inventor of the FPGA and Adaptive SoCs. Xilinx’s highly flexible, programmable silicon, enabled by a suite of advanced software and tools, drove rapid innovation across a wide span of industries and technologies. Xilinx delivered the most dynamic processing technology in the industry, enabling rapid innovation with its adaptable, intelligent computing. In 2022, Xilinx was acquired by AMD and is now the AMD Adaptive and Embedded Computing Group. Follow the AMD LinkedIn page to learn more. https://www.linkedin.com/company/amd